Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24044198 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Anixa Muiños-Bühl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Human Genetics, University of Cologne, 50931 Cologne, Germany. Hauptthemen laut MEDLINE: Muscular Atrophy, Spinal, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, European Union, Center for Molecular Medicine Cologne.
Abstract (Originalsprache)
For SMA patients with only two SMN2 copies, available therapies might be insufficient to counteract lifelong motor neuron (MN) dysfunction. Therefore, additional SMN-independent compounds, supporting SMN-dependent therapies, might be beneficial. Neurocalcin delta (NCALD) reduction, an SMA protective genetic modifier, ameliorates SMA across species. In a low-dose SMN-ASO-treated severe SMA mouse model, presymptomatic intracerebroventricular (i.c.v.) injection of Ncald-ASO at postnatal day 2 (PND2) significantly ameliorates histological and electrophysiological SMA hallmarks at PND21. However, contrary to SMN-ASOs, Ncald-ASOs show a shorter duration of action limiting a long-term benefit. Here, we investigated the longer-term effect of Ncald-ASOs by additional i.c.v. bolus injection at PND28. Two weeks after injection of 500 µg Ncald-ASO in wild-type mice, NCALD was significantly reduced in the brain and spinal cord and well tolerated. Next, we performed a double-blinded preclinical study combining low-dose SMN-ASO (PND1) with 2× i.c.v. Ncald-ASO or CTRL-ASO (100 µg at PND2, 500 µg at PND28). Ncald-ASO re-injection significantly ameliorated electrophysiological defects and NMJ denervation at 2 months. Moreover, we developed and identified a non-toxic and highly efficient human NCALD-ASO that significantly reduced NCALD in hiPSC-derived MNs. This improved both neuronal activity and growth cone maturation of SMA MNs, emphasizing the additional protective effect of NCALD-ASO treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Human Genetics, University of Cologne, 50931 Cologne, Germany.
- Center for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany.
- IONIS Pharmaceuticals, Carlsbad, CA 92010, USA.
- Center for Rare Diseases Cologne, University Hospital of Cologne, 50931 Cologne, Germany.
ORCID-Profile: Anixa Muiños-Bühl, Eleonora Zilio, Brunhilde Wirth
Förderung
- Deutsche Forschungsgemeinschaft
- European Union
- Center for Molecular Medicine Cologne
- German Research Foundation
- European Union’s Horizon 2020 Marie Skłodowska-Curie
Zitieren
APA
Muiños-Bühl, A., Rombo, R., Ling, K. K., Zilio, E., Rigo, F., Bennett, C. F., & Wirth, B. (2023). Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24044198
Vancouver
Muiños-Bühl A, Rombo R, Ling KK, Zilio E, Rigo F, Bennett CF, et al. Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24044198
BibTeX
@article{MuiosBhl2023,
author = {Muiños-Bühl, Anixa and Rombo, Roman and Ling, Karen K and Zilio, Eleonora and Rigo, Frank and Bennett, C Frank and Wirth, Brunhilde},
title = {Long-Term SMN- and Ncald-ASO Combinatorial Therapy in SMA Mice and NCALD-ASO Treatment in hiPSC-Derived Motor Neurons Show Protective Effects},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24044198}
}
EUVIMED